93,725 Medtronic PLC $MDT Shares Sold by Fort Washington Investment Advisors Inc. OH

by · The Cerbat Gem

Fort Washington Investment Advisors Inc. OH decreased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,533,452 shares of the medical technology company’s stock after selling 93,725 shares during the period. Medtronic comprises approximately 1.1% of Fort Washington Investment Advisors Inc. OH’s holdings, making the stock its 19th biggest holding. Fort Washington Investment Advisors Inc. OH’s holdings in Medtronic were worth $218,612,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Mather Group LLC. grew its stake in Medtronic by 45.5% during the 3rd quarter. Mather Group LLC. now owns 3,424 shares of the medical technology company’s stock valued at $295,000 after purchasing an additional 1,070 shares in the last quarter. First Pacific Financial grew its position in shares of Medtronic by 0.8% during the third quarter. First Pacific Financial now owns 43,214 shares of the medical technology company’s stock worth $3,729,000 after buying an additional 364 shares in the last quarter. Summit Financial Strategies Inc. acquired a new stake in shares of Medtronic during the third quarter worth approximately $201,000. Fortitude Family Office LLC grew its position in shares of Medtronic by 126.9% during the third quarter. Fortitude Family Office LLC now owns 490 shares of the medical technology company’s stock worth $42,000 after buying an additional 274 shares in the last quarter. Finally, Godsey & Gibb Inc. increased its stake in shares of Medtronic by 0.5% in the third quarter. Godsey & Gibb Inc. now owns 250,954 shares of the medical technology company’s stock worth $21,655,000 after buying an additional 1,297 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MDT. UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a report on Wednesday. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 4th. Stifel Nicolaus boosted their target price on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Mizuho set a $115.00 target price on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Seventeen equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $102.88.

Check Out Our Latest Stock Report on MDT

More Medtronic News

Here are the key news stories impacting Medtronic this week:

  • Positive Sentiment: Piper Sandler sees a positive read-through for Medtronic. The analyst commentary suggests recent developments may support the investment case for MDT and likely contributed to buying interest. Piper Sandler on Medtronic: Positive Read-Through for MDT
  • Positive Sentiment: Medtronic reported final results for its MiniMed Group exchange offer. The transaction gives shareholders additional clarity on the separation and ownership structure of the diabetes business. The reported 18.3% proration indicates demand exceeded the shares available for exchange, a potentially favorable sign for investor interest in MiniMed and Medtronic’s strategic repositioning. Medtronic Announces Final Results of MiniMed Group Exchange Offer
  • Neutral Sentiment: Medtronic’s dividend remains attractive to income investors. A comparison with Abbott highlighted MDT’s higher current payout, while Abbott has delivered faster dividend growth. This supports Medtronic’s appeal for yield-focused investors but is more of a long-term valuation consideration than a new earnings catalyst. Medtronic Pays More Today: Abbott Raises Its Dividend Faster
  • Neutral Sentiment: Industry reports project strong growth in mHealth and bioelectronic medicine. Medtronic is listed among major participants in both markets, offering potential long-term opportunities, but the reports do not provide company-specific revenue or earnings changes. mHealth Solutions Market Forecasts Growth
  • Negative Sentiment: Short interest in MDT increased significantly. Rising bearish positioning could create volatility and signals that some investors remain skeptical, despite the recent share-price strength. Medtronic Sees Significant Increase in Short Interest

Medtronic Stock Up 1.2%

Medtronic stock opened at $94.14 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a 50-day simple moving average of $90.68 and a 200-day simple moving average of $84.88. The firm has a market capitalization of $120.41 billion, a P/E ratio of 23.19, a P/E/G ratio of 2.12 and a beta of 0.55.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period last year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Stories

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).